July 8, 2019 – MEDESIS PHARMA announces the signing of a collaborative research agreement with TRANSGENE to apply Aonys® technology to the treatment of tumors by oncolytic viruses. This collaboration allows testing of an innovative approach of modulating the tumoral microenvironment, and thus increasing the oncolytic viruses’ activity and their field of use.

An innovative technological platform

MEDESIS PHARMA has an innovative technological platform for the administration of drugs (Aonys®) that allows the administration of modulating unmodified oligonucleotides in a buccal nanoemulsion (in humans), buccal and rectal (in animals), with a protected transport in the blood in HDL-type lipoproteins, then released directly intracellularly by the lipoprotein receptors present on all cells of all tissues, with a passage of the blood-brain barrier.

 

MEDESIS PHARMA will carry out the design, synthesis and formulation of these oligonucleotides in the Aonys® microemulsion. TRANSGENE will conduct pharmacological and mechanistic studies. The use of the Aonys® microemulsion is intended to expand antitumor activity and explore potential new field of oncolytic viruses’ application.

 

About MEDESIS PHARMA:

MEDESIS PHARMA has an innovative technological platform for the administration of drugs (Aonys®, 7 international patents, a system of reverse micelles (water in oil), less than 5 nm, which allows the administration of unmodified oligonucleotides in an buccal nanoemulsion (in humans), buccal and rectal (in animals), with a protected transport in the blood in lipoproteins of the HDL type, then released directly intracellularly by the lipoprotein receptors present on all cells of all tissues, with passage of the blood-brain barrier.

The efficacy of Aonys® technology for unmodified siRNA delivery has been demonstrated in pharmacokinetics with P32-labeled siRNA in the inhibition of prion protein in the brain in rats (publication S. Lehmann, PLoS One vol. 9, Issue 2); and inhibiting tumor growth with unmodified siRNA formulated in Aonys® targeting cyclin D1 (publication in progress).

MEDESIS PHARMA has several programs under development using Aonys® technology:

– Nanolithium® that enters phase 2 on patients for the treatment of psychosis associated with Alzheimer’s disease

– Three products under development for the treatment of large populations contaminated after a nuclear accident (Plutonium decorporation, Cesium decorporation, and Radioprotection)

– A collaborative program with academic teams from McGill University for the treatment of resistant breast cancer in RNA interference.

More information on   www.medesispharma.com

MEDESIS PHARMA SA

L’Orée des Mas, Avenue du Golf, 34670, Montpellier, France

Contact : tessa.olivato@medesispharma.com

Tel : +(33) 467 0303 96

 

Press : Agence Acorelis – Gilles Petitot

gilles.petitot@acorelis.com – +33 620 266 594

Share:Share on Facebook
Facebook